Connect your AI

Haemonetics HAE Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

ICU MedicalICUI

-$136K+92.0%

Merit Medical SystemsMMSI

-$67K+23.0%

RepligenRGEN

-$13.76M—

RevvityRVTY

——

Other financials

Income statement

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

Market cap$3.37B-18.0%

Enterprise value$4.4B-12.5%

P/S2.5×-0.5×

Profitability

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Haemonetics's gain/loss on asset sales?: Haemonetics (HAE) reported gain/loss on asset sales of $178K in Q1 2026.
How has Haemonetics's gain/loss on asset sales changed year-over-year?: Haemonetics's gain/loss on asset sales decreased by 84.2% year-over-year, from $1.13M to $178K.
What is the long-term trend for Haemonetics's gain/loss on asset sales?: Over 4 years (2022 to 2026), Haemonetics's gain/loss on asset sales has grown at a -47.8% compound annual growth rate (CAGR), from $9.6M to $714K.
What does gain/loss on asset sales mean?: Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.